HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BMS 185660
structure in first source
Also Known As:
BMS-185660
Networked:
2
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Terpenes: 1461
Diterpenes: 1470
Taxoids: 2650
BMS 185660: 2
Cyclic Hydrocarbons: 97
Alicyclic Hydrocarbons: 1
Cycloparaffins: 6
Cyclodecanes
Taxoids: 2650
BMS 185660: 2
Experts
1.
Golik, J
: 1 article (01/2000)
2.
Kadow, J
: 1 article (01/2000)
3.
Lee, F Y
: 1 article (01/2000)
4.
Rose, W C
: 1 article (01/2000)
Related Diseases
1.
Carcinoma (Carcinomatosis)
01/01/2000 - "
Also, in the human HCT-116 colon carcinoma model, oral BMS-185660 cured a maximum of seven of eight mice compared with six of seven mice cured with i.v. paclitaxel.
"
2.
Neoplasms (Cancer)
01/01/1997 - "
In each of the tumor models used, the consistently active, and usually the most active, water-soluble derivative was BMS-185660.
"
01/01/1997 - "
Based on the evaluations performed in three distal site tumor models, we conclude that BMS-185660 is a water-soluble paclitaxel derivative with preclinical antitumor activity comparable to that of the parent drug.
"
01/01/2000 - "
Against a human ovarian tumor model with developed resistance to cisplatin (A2780/ cDDP), oral BMS-185660 achieved a maximum LCK of 1.8 compared with i.v. paclitaxel, which produced a maximum 2.4 LCK.
"
Related Drugs and Biologics
1.
Paclitaxel (Taxol)
2.
Cisplatin (Platino)